The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Max - I would argue that we are now producing data on 3 fronts. It's not been published yet bu the trials will be producing data.
Regarding your statement 'Our Cancer rollout which is wildly ambitious again 1 person enrolled' - why do you say it is wildly ambitious ? It doesn't seem that way to me. Also, why do you think that only 1 person has been enrolled - if you are talking about the Modi-1 trial there may be several more enrolled since the FPD.
Scancell has finally reach the stage where we can expect data from 2 trials before the end of the year - the light at the end of the tunnel is rushing towards us. I'd argue that now is the time to be buying.
I would imagine that oil companies and social media don't really mix at the moment given the presence of the anti oil community. Any post by HUR on twitter or Facebook would surely be met with a flood of anti-oil responses.
Hi asimpleinvestor
mariog said 'bonds will be repaid in exactly 15 working days' rather than 15 days.
I agree with the person who said earlier that this smacks of M&A. There is no need to wait until the end of summer to decide whether to drill - they have all the technical info they need to make this decision. It would therefore appear that they are expecting some M&A activity in the next couple of months and only if that falls through will they then announce a plan to drill. I hope that the regular selling into any SP rise isn't to hold the price down to facilitate a planned M&A.
Minor point Johnny but I don't think you can necessarily count biopsies as dead tissue. As long as the biopsy tissue is kept in the right conditions I would imagine that it can remain alive for some time (similar to organ transplants - tissue can be kept alive for a period outside of the body).
I quite like the presentation brief and no fancy waffle - doesn't say much apart from:-
- P8 looks like a good bet and a decision will be reached in roughly the next 2 months (under the current circumstances I doubt there would be much resistance from the regulator so I expect this will go ahead unless outstanding M&A opportunity presents itself)
- there are a companies out there with good assets but not enough cash to complete development, and we may well do a deal with one (or more) of these that will quickly be accretive to shareholder value
Looks like the next 3 months will be very interesting (and hopefully rewarding) for those that choose to buy or hold.
I believe that the company now has a very clear commercial strategy as follows (soonest first):-
1. Commercial partnerships for GlymAb in the Avidimab and ADC / CAR space (I'd expect deals in 3Q/4Q this year)
2. Assuming good Covidity results and SCIB1 results, sell or partner the immunity platform (worth several hundred million plus royalties)
3. Assuming good Modi 1 results partner Modi1 (depending on how good the results are could be worth up to a billion plus royalties)
4. Take Modi2 into the clinic and partner after phase 1 (again could could be very big money)
5. Take the TBC's through phase 1 and possibly further - once proven, partner these for big money
6. After this it will be a case of taking further products into the clinic and partnering once proven
Of course if Modi1 is successful we may start getting some very big take over offers (i.e. several billion) covering the entire set of platforms, so Scancell may not even exist by the end of 2023.
Certainly sounds like there are specific opportunities being looked at Johnny, rather than just wishy washy aspirations to establish commercial partnerships. Looks like they have decided to do the TCB in house and enter into partnerships for ADC and CAR - seems like a good strategy to get all 3 models running with early cash generation form ADC/CAR whilst maximising the return they will get on TCB's (which I guess they see as the most valuable).
Good spot. Maybe we'll see something announced sooner rather than later.
Indeed researcher1 - it also validates the model that AN has described (a small number of large Pharma customers can generate a large number of contracts), and illustrates that CTC analysis must be adding value to the customer's existing trial.